AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02149056 — intervention group
Intervention type: BEHAVIORAL
Intervention: observation
Study NCT02149056 — intervention group
Intervention type: OTHER
Intervention: Impaired Glucose Tolerance
Description: Impaired Glucose Tolerance
Study NCT01944319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine meropenem therapy
Description: Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
Study NCT01944319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem therapy based on a PPK and PD model
Description: Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
Study NCT00501618 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fazaclo
Description: single-arm
Study NCT01270633 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PriMatrix
Description: Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
Study NCT01934192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 50 mg
Description: GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
Study NCT01934192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10 mg
Description: Metoclopramide will be administered IV every 6 h
Study NCT01934192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NG
Description: Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
Study NCT01934192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo NG
Description: Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
Study NCT01934192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo will be administered IV every 6 hours
Study NCT03204721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal photophoresis (ECP)
Description: The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
Study NCT02233400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Study NCT02702427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: virus-specific T-Cells
Description: infusion
Study NCT03282357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant (dermal filler)
Description: Subdermal injection.
Study NCT03282357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse injectable implant (dermal filler)
Description: Subdermal injection.
Study NCT03282357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane injectable implant (dermal filler)
Description: Subdermal injection
Study NCT01270633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Following sharp debridement, moist wound therapy
Study NCT03829813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: 20 to 40 minute music therapy treatment session with a qualified music therapist.
Study NCT03199781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics
Description: Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
Study NCT03105505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 5%
Description: Facial skin application once a night for 3 months.
Study NCT03105505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthomycine 5%
Description: Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
Study NCT03105505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fusidic Acid 1% M/R Eye Drops
Description: viscous eye drops application once a night for 3 months.
Study NCT04133974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: methadone induced memory retrieval-extinction procedure
Description: Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
Study NCT04133974 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: methadone induced memory retrieval-extinction procedure
Description: Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
Study NCT02592954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jojoba oil with broccoli sprout extract
Description: 500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
Study NCT02592954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba oil (placebo)
Description: 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
Study NCT05631821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: differential rod bending with rod contours (MESA Spinal System)
Description: differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
Study NCT04669548 — intervention group
Intervention type: DEVICE
Intervention: Accuryn Monitoring System
Description: The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study NCT03282357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane injectable implant (dermal filler)
Description: Subdermal injection
Study NCT02156869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
Study NCT01252316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training using the Family and Friends CPR Anytime VSI Kit
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
Study NCT01252316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of an In-Hospital CPR Training Model
Description: UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
Study NCT02052219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Description: Blisibimod administered subcutaneously
Study NCT02052219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT04839770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axonpen system
Description: The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation.
Study NCT01911845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study NCT01911845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet
Study NCT01911845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure plus propranolol
Description: For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermoneutral Conditions
Description: Subjects will be exposed to thermoneutral conditions (26 - 28°C)
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water consumption
Description: Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
Study NCT03512756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)
Description: Daily oral therapy for cancer
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tepid water consumption
Description: Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
Study NCT01791114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal consumption
Description: Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
Study NCT06361264 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Karanahan
Description: During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
Study NCT03512756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Gemcitabine, and 5-FU
Description: Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU
Study NCT04291586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
Study NCT04291586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil
Description: Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
Study NCT00664911 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chemotherapy
Study NCT01793662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic aortobifemoral bypass
Description: Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
Study NCT01793662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic aortobifemoral bypass
Description: Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
Study NCT02422095 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections
Description: Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
Study NCT02422095 — intervention group
Intervention type: PROCEDURE
Intervention: EUS of pancreatic cysts
Description: Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
Study NCT01276951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Delivery and return of chocolate
Description: At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
Study NCT01276951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Determination of blood pressure
Description: Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
Study NCT01815450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100
Description: BLI1100 topical cream
Study NCT01815450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100 - modified formulation
Description: BLI1100 topical cream
Study NCT01815450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical cream
Study NCT01276951 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Determination of blood pressure
Description: Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
Study NCT01276951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometric Measurements
Description: The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
Study NCT01310153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prone positioning
Description: newborn babies in prone positioning
Study NCT01310153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine
Description: newborn babies in supine positioning
Study NCT01276951 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anthropometric Measurements
Description: The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
Study NCT01276951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Food Anamnesis
Description: With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
Study NCT02590952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epitinib
Description: The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
Study NCT02044588 — intervention group
Intervention type: BIOLOGICAL
Intervention: HBsAg positive kidney allograft donor
Study NCT02145741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab, low dose, every week (qw)
Description: Patient to receive low dose of Xentuzumab IV
Study NCT02145741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab, middle dose, qw
Description: Patient to receive middle dose of Xentuzumab IV
Study NCT02145741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab, high dose, qw
Description: Patient to receive high dose of Xentuzumab IV
Study NCT00948818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 micrograms
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study NCT00948818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study NCT01879670 — intervention group
Intervention type: DEVICE
Intervention: CircuLite Synergy left ventricular assist device
Study NCT03815396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-101/rhAAT-Fc
Description: INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
Study NCT04136080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vasopressors
Description: control the mean arterial pressure with vasopressors